Status:
TERMINATED
Evaluation of Neointimal Coverage of EES and BMS After Implantation in STEMI Patients by Optical Coherence Tomography
Lead Sponsor:
Harbin Medical University
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Primary percutaneous coronary intervention (PCI) represents the preferred reperfusion strategy for patients with ST-segment elevation myocardial infarction (STEMI), since it is more effective than thr...
Eligibility Criteria
Inclusion
- Age: 18-75 years
- Acute MI with ST-segment elevation, within 12 hours from symptoms onset.
- Length of culprit lesion≤25mm.
- Vessel size in between 2.5 and 4.0 mm.
- Signed patient informed consent.
Exclusion
- Prior administration of thrombolytic therapy.
- Cardiogenic shock.
- Renal failure (Crea≥2.0mg/dL).
- Recent major bleeding.
- Allergy to heparin, aspirin, clopidogrel, everolimus, the polymer components of the Xience V stent, stainless steel, or contrast media.
- Left main disease
- Multi-vessel lesion
- Other hemodynamically significant lesion(s) is present in the infarct vessel (or side branches)
- Angiography demonstrates the infarct lesion to be at the site of a previously implanted stent or in bypass grafts.
- No suitable anatomy for OCT scan.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01875835
Start Date
June 1 2013
End Date
February 1 2016
Last Update
December 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150081